The dipeptidyl peptidase-4 inhibitor (DPP-4i) alogliptin is an oral, antidiabetic treatment that
is approved in many countries to treat patients with type 2 diabetes mellitus (T2DM) …

Liraglutide is a glucagon-like peptide-1 receptor agonist used as a treatment for type 2
diabetes mellitus, which has been expanded for use at a higher dose in weight control …

Incretins reduce glycemic variability (GV) in patients with type 2 diabetes, but it is unknown
whether switching from a combination of basal insulin and a DPP‐4 inhibitor to insulin …

Background As a popular antidiabetic drug, teneligliptin has been used for over 10 years,
but its efficacy and safety have rarely been systematically evaluated. Therefore, a Bayesian …

Aims To evaluate the methodological quality of systematic reviews (SRs), and summarize
evidence of important outcomes from dipeptidyl peptidase-4 inhibitors (DPP4-I) in treating …

Non-alcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic
liver disease. However, the treatment is limited. The aim of this meta-analysis was to …

Introduction: Trelagliptin is a novel, long-acting dipeptidyl peptidase-4 (DPP-4) inhibitor
approved for the treatment of type 2 diabetes mellitus (T2DM) in japan. The safety and …

阿格列汀是二肽基肽酶-4 (DPP-4) 抑制剂中相对较新的一种, 分别于2010 年和2013
年在日本和中国大陆获批上市. 目前在我国获批用于2 型糖尿病患者的单药治疗以及与二甲双胍 …

We explored the therapeutic effects of liraglutide combined with metformin and Diamicron in
elderly patients with type 2 diabetes mellitus (T2DM) and the effects of this regimen on …

抄録 基礎インスリンと Dulaglutide の併用 (A 群) あるいは DPP-4 阻害薬の併用 (B 群)
からインスリンデグルデク/リラグルチド配合製剤 (IDegLira) へ切り替え 6 ヶ月以上継続した症例で …